Prevention and management of osteoporosis in men receiving androgen deprivation therapy: A survey of urologists and radiation oncologists (Q58311504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Padraig Warde

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Angela M. Cheung

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Sameera Rahman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Taha Jaffer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Michael A S Jewett

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

English

0 references

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

126-131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

National practice patterns and time trends in androgen ablation for localized prostate cancer

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Fatigue in patients with prostate cancer receiving hormone therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Long-term effects of androgen deprivation therapy in prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Risk of fracture after androgen deprivation for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

The ten-year rule revisited: accuracy of clinicians’ estimates of life expectancy in patients with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.054

10.1016/J.UROLOGY.2006.01.054

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16844454%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference